EDT talks about the contract manufacturing market at Interphex

By Gareth Macdonald

- Last updated on GMT

Pharma industry demand for outsourced manufacturing is growing and will favour larger contracting players according to Elan Drug Technologies (EDT).

Outsourcing-pharma.com spoke with EDT’s Philip Pratten at Interphex 2011 to find out about the state of the market in six months​ since the firm launched its contract manufacturing services.

Pratten explained that the market is dynamic with reorganisation of the pharmaceutical sectors manufacturing base and search for more ‘strategic partnerships’ creating buoyant demand, at least from EDT’s perspective.

He went on to suggest that this, in part at least, is being driven by EDT’s track record in delivery technologies, which is attractive to a drug industry keen to make manufacturing as cost effective as possible.

The kind of business that they [pharmacaceutical customers] are asking for are real solutions, perhaps using a proprietary Elan technology​,” Pratten explained, adding that customers also the firm’s experience in working with difficult to deliver molecules.

Pratten also shared his thoughts on the future of the contract manufacturing industry, adding that: “It’s going to take strong, larger players to support the kind of outsourcing demands of the future​.”

Related news

Show more

Related products

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers